Elektrofi · 3 months ago
Research Associate, Formulation Development
Elektrofi is a biotech company focused on revolutionizing the delivery of biologic therapies through their innovative Hypercon™ formulation platform. They are seeking a motivated Research Associate in Formulation Development to support drug product development activities and contribute to a multidisciplinary team of scientists and engineers.
Alternative MedicineBiotechnologyTherapeutics
Responsibilities
Contribute to drug product development activities to formulate a wide range of therapeutic biologic modalities into our proprietary Hypercon™ suspension using QbD principles
Utilize scaled-down process models and stress conditions to select formulations that optimize drug product performance, including protein stability and suspension physical properties
Exercise technical discretion in day-to-day laboratory activities
Manage, compile and analyze data using analytical software
Contribute to continuous improvement of systems and processes to improve workflow efficiency
Manage relevant method protocols, present findings and author reports
Qualification
Required
Bachelors with 0+ years experience in Pharmaceutical Sciences, Chemical Engineering, Biochemistry, Bioengineering, Pharmaceutical Engineering, or a related field
Knowledge of protein formulations and degradation mechanisms
Knowledge of statistical methods and design of experiments methodology
Hands-on experience with tangential flow filtration (TFF) of protein solutions and aseptic handling techniques is desirable
Familiarity with standard office software (MS Office, Teams, SharePoint, JMP) and electronic laboratory notebooks
Demonstrated good laboratory skills, organizational skills, and attention to detail
Ability to work in multi-disciplinary teams
Company
Elektrofi
Elektrofi develops hyper concentration microparticle technology for subcutaneous biologic medicine delivery.
Funding
Current Stage
Growth StageTotal Funding
$154.11MKey Investors
National Science Foundation
2025-10-01Acquired
2024-08-22Series C· $112.25M
2022-06-13Series B· $40M
Recent News
The Motley Fool
2025-12-06
MarketScreener
2025-11-19
Company data provided by crunchbase